计算溶液所需的质量、体积或浓度。
This is a demo store. No orders will be fulfilled.
| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| F122999-25mg |
25mg |
现货 ![]() |
| |
| F122999-100mg |
100mg |
现货 ![]() |
| |
| F122999-250mg |
250mg |
现货 ![]() |
| |
| F122999-500mg |
500mg |
现货 ![]() |
| |
| F122999-1g |
1g |
期货 ![]() |
|
| 别名 | 氟达拉滨单磷酸盐 | 2-氟腺嘌呤9-β-D-阿糖腺苷5'-单磷酸盐 | 9-(β-D-阿糖腺苷)-2-氟腺嘌呤5'-单磷酸盐 |
|---|---|
| 英文别名 | HMS2094O11 | MLS004774150 | SMR002544683 | 2F-ara-AMP | 2-Fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine | Fludarabine for system suitability | FLUDARABINE PHOSPHATE (USP-RS) | Q185916 | SR-05000001945-4 | {[(2R,3S,4S,5R)-5-(6-AMINO-2-F |
| 规格或纯度 | ≥99% |
| 英文名称 | Fludarabine phosphate |
| 生化机理 | 氟达拉滨可抑制 DNA 复制,并通过抑制核糖核苷酸还原酶抑制核苷酸代谢。抗肿瘤药。作为一种嘌呤类似物干扰核糖核苷酸还原酶和 DNA 聚合酶。在体内具有抗肿瘤作用(IC 50 = 8-30 μM)。口服有效。 |
| 应用 | 胸苷和脱氧腺苷的类似物,能与dATP竞争结合并整合入DNA中,可抑制DNA合成。 |
| 储存温度 | 2-8°C储存,充氩 |
| 运输条件 | 冰袋运输 |
| 作用类型 | 抑制剂 |
| 作用机制 | 核糖核苷-二磷酸还原酶 RR1 抑制剂 |
| 备注 | 如果有可能,您尽量在使用的当天配置溶液,并在当天使用完它。但是,如果您需要预先配制储备溶液,我们建议您将溶液等份保存在-20°C的密封小瓶中。通常,它们最多可以使用一个月。在使用前和打开样品瓶之前,我们建议您让您的产品在室温下平衡至少1小时。需要更多关于溶解度,用法和处理的建议吗?请访问我们的常见问题(FAQ)页面以获取更多详细信息。 |
| 产品介绍 |
Fludarabine is a purine analog included in the category of DNA-damaging drμgs with well-known efficacy in B-cell chronic lymphocytic leukemia (B-CLL).胸苷和脱氧腺苷的类似物,能与dATP竞争结合并整合入DNA中,可抑制DNA合成。 Fludarabine is a purine analog included in the category of DNA-damaging drugs with well-known efficacy in B-cell chronic lymphocytic leukemia (B-CLL). |
| 纯度 | ≥99% |
| ALogP | -3.1 |
|---|
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | [(2R,3S,4S,5R)-5-(6-amino-2-fluoropurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate |
| INCHI | 1S/C10H13FN5O7P/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(18)5(17)3(23-9)1-22-24(19,20)21/h2-3,5-6,9,17-18H,1H2,(H2,12,14,15)(H2,19,20,21)/t3-,5-,6+,9-/m1/s1 |
| InChi Key | GIUYCYHIANZCFB-FJFJXFQQSA-N |
| Smiles | C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)COP(=O)(O)O)O)O)F)N |
| Isomeric SMILES | C1=NC2=C(N=C(N=C2N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)F)N |
| 分子量 | 365.21 |
| Reaxy-Rn | 24865932 |
| Reaxys-RN link address | https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24865932&ln= |
| 溶解性 | 几乎不溶于水;水中溶解度:8.9 g/l 20 °C;极易溶于二甲基甲酰胺;不溶于乙醚、乙醇 |
|---|---|
| 敏感性 | 易吸潮 |
| 比旋光度 | 12° (C=0.5,H2O) |
| 熔点 | 203°C(dec.)(lit.) |
| 分子量 | 365.210 g/mol |
| XLogP3 | -3.100 |
| 氢键供体数Hydrogen Bond Donor Count | 5 |
| 氢键受体数Hydrogen Bond Acceptor Count | 12 |
| 可旋转键计数Rotatable Bond Count | 4 |
| 精确质量Exact Mass | 365.054 Da |
| 单同位素质量Monoisotopic Mass | 365.054 Da |
| 拓扑极表面积Topological Polar Surface Area | 186.000 Ų |
| 重原子数Heavy Atom Count | 24 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 514.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 4 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 0 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 象形图 | GHS08 |
|---|---|
| 信号词 | 危险 |
| 危险声明 |
H341: 怀疑引起遗传缺陷 H350: 可能导致癌症 H360: 可能损害生育力或未出生的孩子 H361: 怀疑破坏生育力或未出生的孩子 H372: 通过长时间或反复暴露对器官造成损害 |
| 预防措施声明 |
P260: 不要吸入灰尘/烟雾/气体/雾/蒸汽/喷雾。 P264: 处理后要彻底洗手。 P270: 使用本产品时,请勿进食、饮水或吸烟。 P280: 戴防护手套/穿防护服/戴防护眼罩/戴防护面具。 P281: 根据需要使用个人防护设备。 P405: 密闭存放 P501: 将内容物/容器处理到。。。 P203: 使用前,获取、阅读并遵守所有安全说明。 P318: 如果暴露或担心,请就医。 P319: 如果你感到不适,请寻求医疗帮助。 |
| WGK Germany | 3 |
| RTECS | UO7440900 |
| Merck Index | 4126 |
| 1. W Plunkett,P Huang,V Gandhi. (1990-10-01) Metabolism and action of fludarabine phosphate.. Seminars in oncology, 17 ((5 Suppl 8)): (3-17). [PMID:1699280] |
| 2. D D Von Hoff. (1990-10-01) Phase I clinical trials with fludarabine phosphate.. Seminars in oncology, 17 ((5 Suppl 8)): (33-38). [PMID:1699281] |
| 3. H M Kantarjian,J R Redman,M J Keating. (1990-10-01) Fludarabine phosphate therapy in other lymphoid malignancies.. Seminars in oncology, 17 ((5 Suppl 8)): (66-70). [PMID:1699285] |
| 4. G Rodriguez. (1994-01-01) Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.. Investigational new drugs, 12 ((2)): (75-92). [PMID:7532163] |
| 5. L E Robertson,M J Keating. (1993-01-01) Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions.. Cancer treatment and research, 64 (105-119). [PMID:7680874] |
| 6. P McLaughlin,L E Robertson,M J Keating. (1996-01-01) Fludarabine phosphate in lymphoma: an important new therapeutic agent.. Cancer treatment and research, 85 (3-14). [PMID:9043771] |
| 7. Sudipta Das,Claudette St Croix,Misty Good,Jie Chen,Jinming Zhao,Sanmei Hu,Mark Ross,Michael M Myerburg,Joseph M Pilewski,John Williams,Sally E Wenzel,Jay K Kolls,Anuradha Ray,Prabir Ray. (2020-06-25) Interleukin-22 Inhibits Respiratory Syncytial Virus Production by Blocking Virus-Mediated Subversion of Cellular Autophagy.. iScience, 23 ((7)): (101256-101256). [PMID:32580124] |
| 8. M J Keating. (1990-10-01) Fludarabine phosphate in the treatment of chronic lymphocytic leukemia.. Seminars in oncology, 17 ((5 Suppl 8)): (49-62). [PMID:1699283] |
| 9. B D Cheson. (1990-10-01) Issues for the future development of fludarabine phosphate.. Seminars in oncology, 17 ((5 Suppl 8)): (71-78). [PMID:1699286] |
| 10. H G Chun,B Leyland-Jones,B D Cheson. (1991-01-01) Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 9 ((1)): (175-188). [PMID:1702143] |
| 11. Míriam Molina-Arcas,Beatriz Bellosillo,F Javier Casado,Emili Montserrat,Joan Gil,Dolors Colomer,Marçal Pastor-Anglada. (2002-11-02) Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia.. Blood, 101 ((6)): (2328-2334). [PMID:12411296] |
| 12. Francesca Ricci,Alessandra Tedeschi,Enrica Morra,Marco Montillo. (2009-05-14) Fludarabine in the treatment of chronic lymphocytic leukemia: a review.. Therapeutics and clinical risk management, 5 ((1)): (187-207). [PMID:19436622] |
| 13. Julien Valton,Valérie Guyot,Alan Marechal,Jean-Marie Filhol,Alexandre Juillerat,Aymeric Duclert,Philippe Duchateau,Laurent Poirot. (2015-06-11) A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy.. Molecular therapy : the journal of the American Society of Gene Therapy, 23 ((9)): (1507-1518). [PMID:26061646] |
| 14. Andrea Celeghin,Silvia Giunco,Riccardo Freguja,Manuela Zangrossi,Silvia Nalio,Riccardo Dolcetti,Anita De Rossi. (2016-12-30) Short-term inhibition of TERT induces telomere length-independent cell cycle arrest and apoptotic response in EBV-immortalized and transformed B cells.. Cell death & disease, 7 ((12)): (e2562-e2562). [PMID:28032863] |
| 15. Min Chen,Sheng Zhao,Wen-Huan Guo,Yi-Ping Zhu,Lei Pan,Zhi-Wen Xie,Wen-Lan Sun,Jun-Tao Jiang. (2020-08-19) Maternal exposure to Di-n-butyl phthalate (DBP) aggravate gestational diabetes mellitus via FoxM1 suppression by pSTAT1 signalling.. Ecotoxicology and environmental safety, 205 (111154-111154). [PMID:32810643] |